NDRA
NASDAQENDRA Life Sciences Inc.
Price$4.32+0.74 (+20.67%)
2026-03-052026-06-08
News · 26 weeks21-25%
2025-12-142026-06-07
Mix1290d
- SEC Filings7(58%)
- Other5(42%)
Latest news
25 items- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form RW filed by ENDRA Life Sciences Inc.RW - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value. ENDRA will continue to execute on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process. Demonstr
- SECSEC Form S-8 filed by ENDRA Life Sciences Inc.S-8 - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form 10-Q filed by ENDRA Life Sciences Inc.10-Q - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and ReproducibilityResults confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independen
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form 10-K filed by ENDRA Life Sciences Inc.10-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value. The Company intends to continue executing on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder ValueBoard to evaluate a range of alternatives while continuing to support core business priorities ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company. E
- INSIDERChief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERChief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- PRENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient CareAchieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of ad
- INSIDERDirector Digiandomenico Anthony was granted 60,324 shares, increasing direct ownership by 79% to 136,589 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERDirector Harsh Michael was granted 60,324 shares, increasing direct ownership by 1,120% to 65,710 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERChief Financial Officer Jacroux Richard was granted 20,000 shares (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERDirector Basenese Lou was granted 60,324 shares, increasing direct ownership by 1,120% to 65,709 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERChief Executive Officer Tokman Alexander Y was granted 75,000 shares, increasing direct ownership by 1,500,000% to 75,005 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial UseFeasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%. These thresholds separate mild, moderate and severe disease, are widely
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form SCHEDULE 13D filed by ENDRA Life Sciences Inc.SCHEDULE 13D - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECSEC Form 424B4 filed by ENDRA Life Sciences Inc.424B4 - ENDRA Life Sciences Inc. (0001681682) (Filer)
NDRA FAQ
6 questionsWhat does ENDRA Life Sciences Inc. do?
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about...Where does NDRA stock trade?
ENDRA Life Sciences Inc. (NDRA) is listed on NASDAQ.What sector and industry is NDRA in?
ENDRA Life Sciences Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did ENDRA Life Sciences Inc. go public?
ENDRA Life Sciences Inc. (NDRA) completed its IPO in 2017.What companies are similar to NDRA?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare NDRA side-by-side with any of them on Quantisnow.How can I track NDRA on Quantisnow?
Quantisnow aggregates ENDRA Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NDRA to receive live email and push alerts on every new disclosure.